Delving into the Latest Updates on Autologous dendritic cell cancer vaccine(National Cancer Institute) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Dendritic cell vaccine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

National Cancer Institute

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells. Biological therapies, such as Granulocyte-macrophage colony-stimulating factor (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing. Combining different types of biological therapies may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying giving vaccine therapy together with dendritic cells to see how well it works compared to giving vaccine therapy together with GM-CSF in treating patients with liver or lung metastases from colorectal cancer removed by surgery.

Start Date01 Feb 2005

Sponsor / Collaborator

Duke University

[+1]

NCT00103116

/ CompletedPhase 2IIT

Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC)

RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells.
PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.

Start Date01 Oct 2004

Sponsor / Collaborator

University of Kentucky

[+1]

NCT00068510

/ CompletedPhase 1IIT

Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with malignant glioma.

Start Date01 Jun 2003

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Autologous dendritic cell cancer vaccine(National Cancer Institute)

Login to view more data

100 Translational Medicine associated with Autologous dendritic cell cancer vaccine(National Cancer Institute)

Login to view more data

100 Patents (Medical) associated with Autologous dendritic cell cancer vaccine(National Cancer Institute)

Login to view more data

100 Deals associated with Autologous dendritic cell cancer vaccine(National Cancer Institute)

Login to view more data